Nemiralisib
- Generic Name
- Nemiralisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28N6O
- CAS Number
- 1254036-71-9
- Unique Ingredient Identifier
- OEP8JJ3OZR
- Background
Nemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT03398421
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT02593539
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath